Can the shingles vaccine protect transplant patients? new study aims to find out
NCT ID NCT06262776
First seen Apr 29, 2026 · Last updated Jun 20, 2026 · Updated 8 times
Summary
This study tests the shingles vaccine (SHINGRIX) in 160 people: transplant recipients on different immunosuppressant drugs and their healthy housemates. Researchers will measure immune responses at five time points over a year to see if the vaccine works well in these groups. The goal is to understand how different medications affect vaccine effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant zoster vaccine adjuvanted (SHINGRIX)
What this could lead to
If it works, this could show that the shingles vaccine is effective for transplant patients on various immunosuppressants, helping protect them from shingles.
What could go wrong
This is an early-phase study with only 160 participants, so results may not apply to all transplant patients. The vaccine might not produce strong immunity in those on certain medications.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.